Tocilizumab attenuated the inflammatory response and reduced troponin T release in NSTEMI patients compared to placebo.
Does a single dose of tocilizumab reduce inflammation and troponin T release in patients with NSTEMI?
Patients with non-ST-elevation myocardial infarction (NSTEMI)
Single dose of tocilizumab (interleukin-6 receptor antagonist)
Placebo
Inflammation and troponin T releasesurrogate
A single dose of tocilizumab attenuates inflammation and PCI-related troponin T release in patients with NSTEMI.
Absolute Event Rate: 0% vs 0%
Tocilizumab attenuated the inflammatory response and primarily PCI-related TnT release in NSTEMI patients.
Building similarity graph...
Analyzing shared references across papers
Loading...
Ola Kleveland
St Olav's University Hospital
Gabor Kunszt
Institució Catalana de Recerca i Estudis Avançats
Marte Bratlie
RemovAid (Norway)
European Heart Journal
University of Oslo
Norwegian University of Science and Technology
Oslo University Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Kleveland et al. (Sun,) reported a other. Tocilizumab attenuated the inflammatory response and reduced troponin T release in NSTEMI patients compared to placebo.
synapsesocial.com/papers/696308dd7247ee1819be2f36 — DOI: https://doi.org/10.1093/eurheartj/ehw171
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: